PepEvolutionTesamorelin
Egrifta
The only FDA-approved GHRH analogue — proven for HIV-associated visceral fat, compounded off-label, conservative safety profile.
Verdict — B · Viable
A real FDA approval and clean phase-3 evidence base, but a narrow indication, daily injection burden, and meaningful glucose/IGF-1 concerns hold it at B. Stronger than most GH secretagogues; obtain it compounded from a licensed pharmacy.
Overview
Tesamorelin is a synthetic GHRH analogue FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy, with phase-3 RCT evidence from Falutz et al. demonstrating significant visceral fat reduction. It is also used off-label by compounding pharmacies for general GH-axis support and body composition. Safety concerns include glucose intolerance (raises IGF-1), fluid retention, and injection site reactions; the indication is narrow and the off-label use case is less supported.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Want a clinical path?
Talk to a licensed provider about Tesamorelin and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice — for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.
Free. Unsubscribe anytime. Research/educational content only.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.